Since resistance is a major impediment to long-term survival for patients with metastatic melanoma, and ABL kinases are activated by ERK pathway components (BRAF, ERK) and activate ERK16, we tested whether ABL1/2 drive BRAFi or BRAFi/MEKi resistance. This evidence concerns the gene BRAF and metastatic melanoma.